source
- FDA approves vepdegestrant for ESR1-mutated ER-positive advanced breast cancerOn May 1, 2026 the FDA gave its first approval to vepdegestrant, an oral selective estrogen receptor degrader, for adult patients with estrogen receptor-positive, HER2-negative breast cancer that c…
- Isomorphic Labs secures $2.1 billion Series B, cementing AI drug-discovery leadershipIsomorphic Labs announced on Tuesday that it has closed a $2.1 billion Series B financing round. The sizable round underscores the company’s position as a bellwether for using artificial intellige…